CD274 and cervical cancer: Although PD-L1 expression is a biomarker clinically approved for immunotherapy in metastatic or recurrent cervical cancer (based on the KEYNOTE-158 and -826 trials), its prognostic significance in treatment-naive invasive squamous cell carcinoma (SCC) remains unclear [12,13].